Clinical trials: Immunodeficiency
HIV Associated Cognitive Motor Complex
Effect of Galantamine on Inflammation and Cognition
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be…
- Trial name
- CHI (NCT03384784)
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Primary Immunodeficiency
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
The purpose of the study is to determine whether biweekly (every 2 weeks) administration of Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%) produces a steady-state area under the…
- Trial name
- NCT04566692
- Testing
- IGSC 20%
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Grifols Therapeutics LLC
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults.
- Trial name
- NCT05393271
- Testing
- VH4011499, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal…
- Trial name
- NCT03408899
- Testing
- PC-1005 gel
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
This study will examine whether interleukin-2 (IL-2) plus antiretroviral therapy (ART) slows HIV disease progression in patients with low CD4+ T cell counts compared with patients taking ART alone.
- Trial name
- SILCAAT (NCT00013611)
- Testing
- Proleukin
- Where
- United States
- Volunteers
- 1,695 people
- Sponsor
- University of Minnesota
HIV Infections
AmbassADDOrs for Health Study
The goal of the study is to evaluate Malkia Klabu ("Queen Club") in Tanzania, a loyalty program intervention that creates adolescent girls and young women (AGYW)-friendly drug shops where AGYW can access HIV prevention services…
- Trial name
- ADDO (NCT05357144)
- Testing
- Loyalty card program at drug shops & supply of HIVST and SRH products, Comparison drug shops
- Where
- 2 sites in Tanzania
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hiv, Aids
Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
The objectives of this study are to pilot test the effect of reducing time to spaced-out appointments from 18 to 6 months for newly-diagnosed people living with HIV (PLWH) in Rwanda who have initiated antiretroviral therapy…
- Trial name
- NCT04567693
- Testing
- Early spaced-out appointments
- Where
- Rwanda
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Hiv, HIV Infections
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease
N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir.
- Conditions
- Hiv, HIV Infections, AIDS
- Trial name
- NCT04808908
- Testing
- N-803
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Minnesota
HIV, HIV Infections
Extending HIV Care Beyond the Rural Health Center
The objective of this application is to develop and assess a system which uses non-clinician extenders to provide selected aspects of HIV care in rural western Kenya.
- Trial name
- NCT00371540
- Testing
- Home visit by community care coordinators
- Where
- Kenya
- Volunteers
- 208 people
- Sponsor
- Indiana University
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, AIDS
HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
Human Immunodeficiency Virus (HIV) infected patients in the HIV registries of Johns Hopkins University, University of North Carolina and Vanderbilt University will be followed in the routine clinical care to estimate the rates of…
- Trial name
- NCT01339416
- Volunteers
- 8,202 people
- Sponsor
- ViiV Healthcare
HIV Infections
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
Despite viral suppression, antiretroviral therapy (ART) does not restore CD4+ T-cell counts in some subjects. The purpose of this study is to assess whether adding maraviroc (MVC) to a suppressive ART will result in a significant…
- Trial name
- NCT00709111
- Testing
- Maraviroc
- Where
- 29 sites in United States
- Volunteers
- 34 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection, Alcohol Drinking
Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection
This study will examine whether moderate alcohol use in the context of HIV infection exacerbates inflammatory signaling in the immune system and brain.
- Trial name
- NCT04050735
- Testing
- Alcohol, ethyl, moderate dose
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Brown University
HIV Infections
Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of two HIV-1 pDNA vaccines: p24CE1/2 pDNA and p55^gag pDNA administered with IL-12 pDNA adjuvant, given by intramuscular (IM) injection with…
- Trial name
- HVTN119 (NCT03181789)
- Testing
- p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant
- Where
- 3 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Coronary Heart Disease
High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV
HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily) in HIV-infected persons taking…
- Trial name
- HILLCLIMBER (NCT02841774)
- Testing
- Pravastatin, Rosuvastatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Feinstein
HIV
Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY
The project presented here will be the first prospective, randomized evaluation of the effect of ART on the structure and function of the gut microbiome.
- Trial name
- NCT03029689
- Testing
- Raltegravir, Current ART
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Human Immunodeficiency Virus (HIV)
Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts
This study aims to evaluate the effect of Vitamin D3 supplementation on inflammatory markers and immune status in patients with HIV who are receiving antiretroviral therapy.
- Trial name
- NCT07553052
- Testing
- Vitamin D3, Antiretroviral (ARV) medications
- Where
- Indonesia
- Volunteers
- 20 people
- Sponsor
- Universitas Sebelas Maret
HIV Infections, Acquired Immunodeficiency Syndrome
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed.
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- CRRT (NCT00000134)
- Testing
- Ganciclovir, Foscarnet
- Volunteers
- 279 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
Background: HIV affects millions of people. The disease may "hide" in the brain, even in people with well-controlled HIV without cancer. Then it may "wake up" and continue.
- Trial name
- NCT03239899
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV Infections
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
- Trial name
- HVTN 135 (NCT04607408)
- Testing
- CH505TF gp120, GLA-SE adjuvant
- Where
- South Africa
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network